Related Experiment Video
Updated: Jun 26, 2025
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis
Zi-Jing Li1, William Pat Fong1, Dong-Sheng Zhang1
1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 510060, Guangzhou, P. R. China.
Abstract:
Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) is a rare and chemotherapy-refractory subtype that lacks established and effective treatment strategies. Additionally, the efficacy and safety of ALK inhibitors (ALKi) in CRC remain undetermined. Herein, we examined a series of ALK-positive CRC patients who underwent various lines of ALKi treatment. Notably, we detected an ALK 1196M resistance mutation in a CRC patient who received multiple lines of chemotherapy and ALKi treatment. Importantly, we found that Brigatinib and Lorlatinib demonstrated some efficacy in managing this patient, although the observed effectiveness was not as pronounced as in non-small cell lung cancer cases. Furthermore, based on our preliminary analyses, we surmise that ALK-positive CRC patients are likely to exhibit inner resistance to Cetuximab. Taken together, our findings have important implications for the treatment of ALK-positive CRC patients.
Insights
Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) is rare and hard to treat. ALK inhibitors show some promise, but resistance and Cetuximab resistance are challenges.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) represents a rare, chemotherapy-refractory subtype with limited therapeutic options.
- The efficacy and safety of anaplastic lymphoma kinase inhibitors (ALKi) in CRC are not well-established.
Purpose of the Study:
- To investigate the treatment outcomes of ALK-positive CRC patients receiving ALKi therapy.
- To identify resistance mechanisms and potential therapeutic strategies for this rare cancer subtype.
Main Methods:
- Retrospective analysis of ALK-positive CRC patients treated with various ALKi.
- Detection of resistance mutations, including ALK 1196M.
- Evaluation of treatment response to Brigatinib and Lorlatinib.
Main Results:
- An ALK 1196M resistance mutation was identified in a patient with advanced CRC.
- Brigatinib and Lorlatinib showed partial efficacy in managing this resistant case, though less than in non-small cell lung cancer.
- Preliminary data suggest intrinsic resistance to Cetuximab in ALK-positive CRC.
Conclusions:
- ALK inhibitors offer potential, but resistance mechanisms like the ALK 1196M mutation need consideration.
- ALK-positive CRC may exhibit inherent resistance to Cetuximab, impacting treatment choices.
- Further research is crucial for optimizing ALKi therapy and managing resistance in ALK-positive CRC.
